The mechanisms of hypercalcaemia were assessed in 20 hypercalcaemic patients with breast cancer. Abnormalities suggestive of a PTH-related peptide (PTHrP) mechanism were observed in up to 60% of cases; urinary cyclic adenosine monophosphate (UcAMP) was elevated in nine patients (45%), renal tubular reabsorption of calcium (RTRCa) was elevated in nine (45%) and the renal tubular threshold for phosphate reabsorption (TmPO4) depressed in 12 (60%). While TmPO4 was lower in patients with high UcAMP, there was no consistent relationship between RTRCa and UcAMP or UcAMP and the extent of bone metastases.
In a control group of nine normocalcaemic breast cancer patients, bone resorption as assessed by urinary calcium/creatinine ratio was slightly increased but UcAMP, RTRCa and TmPO4 were generally normal.
These observations indicate that a PTHrP-mediated mechanism of hypercalcaemia may be operative in up to 60% of patients with breast cancer, irrespective of the presence or extent of bone metastases.
MundyCMartinTJ. The hypercalcaemia of malignancy: Pathogenesis and management. Metabolism1982; 31: 1247–77.
2.
MundyGRIbbotsonKJD'SouzaSMSimpsonELJacobsJWMartinTJ. The hypercalcaemia of cancer—clinical implications and pathogenic mechanisms. New Eng J Med1984; 310: 1718–27.
3.
IsalesCCarcangiuMLStewartAF. Hypercalcaemia in breast cancer—reassessment of the mechanism. Am J Med1987; 82: 1143–7.
4.
PercivalRCYatesAJPGrayRESMechanisms of malignant hypercalcaemia in carcinoma of the breast. Br Med J1985; 291: 776–9.
5.
KempBEMoselyJMRoddaCPParathyroid hormone related protein of malignancy: Active synthetic fragments. Science1987; 238: 1568–70.
6.
GardnerMDDryburghFJFyffeJAJenkinsAS. Predictive value of derived calcium figures based on the measurement of ionised calcium. Ann Clin Biochem1981; 18: 106–9.
7.
BeastallGHMcKellarNBoyleITPreoperative localisation of parathyroid tumours using neck vein catheterisation and radioimmunoassay of parathyroid hormone; the Glasgow experience. Scot Med J1983; 28: 146–52.
8.
LogueFCFraserWDO'ReillyDStJBeastallGH. The circadian rhythm of intact parathyroid hormone (1–84) and nephrogenous cyclic adenosine monophosphate in normal man. J Endocrinol1989; 121: R1–R3.
9.
O'ReillyDStJFraserWDPennyMDArginine infusion blocks the action of parathyroid hormone but not arginine vasopressin on the renal tubule in man. J Endocrinol1986; 111: 501–6.
10.
BroadusAEMahaffeyJEBartterFONeerRM. Nephrogenous cyclic adenosine monophosphate as a parathyroid function test. J Clin Invest1977; 60: 771–83.
11.
PeacockMRobertsonWGNordinBEC. Relation between serum and urinary calcium with particular reference to parathyroid hormone. Lancet1969; i: 384–6.
12.
WaltonRJBijvoetOLM. Nomogram for the derivation of renal threshold phosphate concentration. Lancet1975; ii: 309–10.
13.
RalstonSFogelmanIGardnerMBoyleIT. Hypercalcaemia and metastatic bone disease: Is there a causal link?Lancet1982; ii: 903–5.
14.
MoselyJMKubotaMDiepenbach-JaggerHParathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA1987; 84: 5048–52.
15.
StrewlerGJSternPHJacobsJWParathyroid hormone-like protein from human renal carcinoma cells: Structural and functional homology with parathyroid hormone. J Clin Invest1987; 80: 1803–7.
16.
StewartAFHorstRDeftosLJCadmanECLangRBroadusAE. Biochemical evaluation of patients with cancer associated hypercalcaemia: Evidence for humoral and non-humoral groups. New Eng J Med1980; 303: 1377–83.
17.
BurtisWJWuTEBunchCIdentification of a novel 17000 dalton parathyroid hormone like adenylate cyclase-stimulating protein from a tumour associated with humoral hypercalcaemia of malignancy. J Biol Chem1987; 212: 7151–6.
18.
SchusslerGCVersoMANemetoT.Phosphaturia in hypercalcaemic breast cancer patients. J Clin Endocrinol Metab1972; 35: 497–504.
19.
SleeboomHPBijvoetOLMVanOosteromATGleedJHO'RiordanJLH. Comparison of intravenous (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate and volume repletion in tumour induced hypercalcaemia. Lancet1983; ii: 239–43.
20.
RudeRKSharpCFJFredericksRSUrinary and nephrogenous adenosine 3–5 monophosphate in the hypercalcaemia of malignancy. J Clin Endocrinol Metab1981; 52: 765–71.
21.
MundyGR. Calcium Homeostasis: Hypercalcaemia and Hypocalcaemia. London: Martin Dunitz, 1989; 57.
22.
RalstonSHCowanRAGardnerMDFraserWDMarshallEBoyleIT. Comparison of intestinal calcium absorption and circulating 1,25 dihydroxyvitamin D levels in malignancy associated hypercalcaemia and primary hyperparathyroidism. Clin Endocrinol1987; 26: 281–91.
23.
FukomotoSMatsumotoTYamotoHSuppression of serum 1,25 dihydroxyvitamin D in humoral hypercalcaemia of malignancy is caused by elaboration of a factor that inhibits renal 1,25 dihydroxyvitamin D3 production. Endocrinology1989; 124: 2057–62.
24.
HarinckHIJBiyvoetOLMPlantinghASTRole of bone and kidney in tumour induced hypercalcaemia and its treatment with bisphosphonate and sodium chloride. Am J Med1987; 82: 1133–42.
25.
ShawJWOldhamSBBethuneJEFichmanMP. Parathyroid hormone (PTH)-mediated rise in urinary cyclic AMP (UcAMP) during acute extracellular fluid (ECF) expansion natriuresis in man. J Clin Endocrinol Metab1974; 39: 311–15.
